When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
DERM - Dermira up 3% premarket on start of late-stage development of lebrikizumab
Journey Medical Corporation
Dosing is underway in a Phase 3 clinical trial evaluating Dermira's (NASDAQ:DERM) lebrikizumab, an IL-13 inhibitor, in patients at least 12 years old with moderate-to-severe atopic dermatitis (AD).
More news on: Dermira, Inc., Almirall, S.A., Healthcare stocks news, Stocks on the move,